Trial
NCT00110149
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Beth Israel Deaconess Medical Center
Collaborators
—
Condition
Lymphoma
Intervention
rituximab
Why stopped
Company withdrew drug supply
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-11-21